intended to form the basis of any investment decision or any other decision in respect of the proposed Business Combination. OACBs shareholders and other interested persons are advised to
read, when available, the preliminary proxy statement/prospectus and the amendments thereto and the definitive proxy statement/prospectus and other documents filed in connection with the proposed Business Combination, as these materials will contain
important information about Alvotech, OACB and the proposed Business Combination. When available, the definitive proxy statement/prospectus and other relevant materials for the proposed Business Combination will be mailed to shareholders of OACB as
of a record date to be established for voting on the proposed Business Combination. Shareholders of OACB will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus and other documents
filed with the SEC, without charge, once available, at the SECs website at www.sec.gov, or by directing a written request to: OACB, 333 South Grand Avenue, 28th Floor, Los Angeles, California 90071.
Participants in the Solicitation
OACB and Alvotech and
their directors and executive officers may be deemed participants in the solicitation of proxies from OACBs shareholders with respect to the Business Combination. A list of the names of those directors and executive officers and a description
of their interests in OACB is contained in OACBs annual report on Form 10-K/A for the fiscal year ended December 31, 2020 (as amended December 13, 2021), which was filed with the SEC and is
available free of charge at the SECs web site at www.sec.gov, or by directing a written request to OACB, 333 South Grand Avenue, 28th Floor, Los Angeles, California 90071. Additional information regarding the interests of such
participants will be contained in the proxy statement/prospectus for the proposed Business Combination when available.
Alvotech Lux Holdings S.A.S and
its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of OACB in connection with the proposed Business Combination. A list of the names of such directors and executive
officers and information regarding their interests in the proposed Business Combination will be included in the proxy statement/prospectus for the proposed Business Combination when available.
Forward-Looking Statement
Certain statements in this
communication may be considered forward-looking statements. Forward-looking statements generally relate to future events or the future financial operating performance of OACB or Alvotech. For example, Alvotechs expectations
regarding future growth, results of operations, performance, future capital and other expenditures including the development of critical infrastructure for the global healthcare markets, competitive advantages, business prospects and opportunities
including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events; the FDAs communicated timeline to inspect the requisite facilities and to reach a
decision on the BLA application; and the potential approval and commercial launch of AVT02. In some cases, you can identify forward-looking statements by terminology such as may, should, expect,
intend, will, estimate, anticipate, believe, predict, potential or continue, or the negatives of these terms or variations of them or similar
terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking
statements are based upon estimates and assumptions that, while considered reasonable by OACB and its management, and Alvotech and its management, as the case may be, are inherently uncertain and are inherently subject to risks, variability and
contingencies, many of which are beyond OACBs and Alvotechs control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the occurrence of any event, change or
other